A compound selected from Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein: X is N; R 1, R 2 and R 3 are independently selected from H, -C NH 2, C 6 -C 20 aryl, C 3 -C 12 carbocyclyl, C 2 -C 20 heterocyclyl, C 1 -C 20 heteroaryl, -NH 2, -NH-(C 6 -C 20 aryl), -NH-(C 1 -C 20 heteroaryl), -C -(C 1 -C 12 alkyl), -C -(C 3 -C 12 carbocyclyl), -NH-(C 1 -C 12 alkylene)-(C 2 -C 20 heterocyclyl), -NH-(C 1 -C 20 heteroaryl)-(C 2 -C 20 heterocyclyl),-NHC -(C 3 -C 12 carbocyclyl), - NHC -(C 1 -C 12 alkyl), -(C 6 -C 20 aryl)-C -(C 2 -C 20 heterocyclyl), and -(C 1 -C 20 heteroaryl)-(C 2 -C 20 heterocyclyl); or R 1 and R 2 optionally form a fused six-membered aryl, carbocyclyl, heterocyclyl, or heteroaryl ring; at least one of R 1, R 2 and R 3 is -C NH 2; R 4 is selected from H, F, Cl, CN, -CH 2 OH, -CH(CH 3)OH, -C(CH 3) 2 OH,-CH(CF 3)OH, -CH 2 F, -CHF 2, -CH 2 CHF 2, -CF 3, -C NH 2, -C NHCH 3, -C N(CH 3) 2, -NH 2, -NHCH 3, -N(CH 3) 2, -NHC CH 3, -OH, -OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OH, cyclopropyl, cyclopropylmethyl, 1-hydroxycyclopropyl, imidazolyl, pyrazolyl, 3-hydroxy-oxetan-3-yl, oxetan-3-yl, and azetidin-1-yl; R 5 is H, F, Cl, or CN; R 6 is selected from the structures: where the wavy line indicates the site of attachment; and alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, -CN, -CH 3, -CH 2 CH 3, - CH(CH 3) 2, -CH 2 CH(CH 3) 2, -CH 2 NH 2, -CH 2 NHCH 3, -CH 2 N(CH 3) 2, -CH 2 OH, -CH 2 OCH 3, -CH 2 CH 2 OH, -C(CH 3) 2 OH, -CH CH(CH 3) 2, -C(CH 3) 2 CH 2 OH, -CH 2 CH 2 SO 2 CH 3, - CH 2 OP 2, -CH 2 F, -CHF 2, -CF 3, -CH 2 CF 3, -CH 2 CHF 2, -CH(CH 3)CN, - C(CH 3) 2 CN, -CH 2 CN, -CO 2 H, -COCH 3, -CO 2 CH 3, -CO 2 C(CH 3) 3, -COCH CH 3, - CONH 2, -CONHCH 3, -CON(CH 3) 2, -CONH(CH 2 CH 2 N(CH 3) 2), -C(CH 3) 2 CONH 2, -NH 2, - NHCH 3, -N(CH 3) 2, -NHCOCH 3, -N(CH 3)COCH 3, -NHS 2 CH 3, - N(CH 3)C(CH 3) 2 CONH 2, -N(CH 3)CH 2 CH 2 S 2 CH 3, -NO 2, =O, -OH, -OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OCH 3, -OCH 2 CH 2 OH, -OCH 2 CH 2 N(CH 3) 2, -OP 2, -S 2 N(CH 3) 2, - SCH 3, -S 2 CH 3, -S 3 H, cyclopropyl, oxetanyl, azetidinyl, 1-methylazetidin-3-yl)oxy, N-methyl-N-oxetan-3-ylamino, azetidin-1-ylmethyl, pyrrolidin-1-yl, and morpholino. X is N; R 1, R 2 and R 3 are independently selected from H, -C NH 2, C 6 -C 20 aryl, C 3 -C 12 carbocyclyl, C 2 -C 20 heterocyclyl, C 1 -C 20 heteroaryl, -NH 2, -NH-(C 6 -C 20 aryl), -NH-(C 1 -C 20 heteroaryl), -C -(C 1 -C 12 alkyl), -C -(C 3 -C 12 carbocyclyl), -NH-(C 1 -C 12 alkylene)-(C 2 -C 20 heterocyclyl), -NH-(C 1 -C 20 heteroaryl)-(C 2 -C 20 heterocyclyl),-NHC -(C 3 -C 12 carbocyclyl), - NHC -(C 1 -C 12 alkyl), -(C 6 -C 20 aryl)-C -(C 2 -C 20 heterocyclyl), and -(C 1 -C 20 heteroaryl)-(C 2 -C 20 heterocyclyl); or R 1 and R 2 optionally form a fused six-membered aryl, carbocyclyl, heterocyclyl, or heteroaryl ring; at least one of R 1, R 2 and R 3 is -C NH 2; R 4 is selected from H, F, Cl, CN, -CH 2 OH, -CH(CH 3)OH, -C(CH 3) 2 OH,-CH(CF 3)OH, -CH 2 F, -CHF 2, -CH 2 CHF 2, -CF 3, -C NH 2, -C NHCH 3, -C N(CH 3) 2, -NH 2, -NHCH 3, -N(CH 3) 2, -NHC CH 3, -OH, -OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OH, cyclopropyl, cyclopropylmethyl, 1-hydroxycyclopropyl, imidazolyl, pyrazolyl, 3-hydroxy-oxetan-3-yl, oxetan-3-yl, and azetidin-1-yl; R 5 is H, F, Cl, or CN; R 6 is selected from the structures: